REGULATORS in China have confirmed they plan to accept clinical data from overseas trials in order to speed up drug approvals.
According to Wu Zhen, deputy head of the China Food and Drug Administration, the plan aims to improve the accessibility of new drugs, some of which have been available in other countries for up to seven years before making it to market in China.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Oct 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Oct 17
